| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 1.3 | 0.8 |
| Profit before tax | 0.5 | 0.1 |
| Net income | 0.5 | 0.2 |
| EPS (diluted, $ a share) | $0.04 | $0.01 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | +223.0% |
|---|---|
| Revenue, year on year | +60.6% |
| Operating margin | -38.0% |
10-Q filed with the SEC, NASDAQ: TXMD. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
TherapeuticsMD, Inc.: key numbers
- Share price
- $1.81Close, Nov 16
- Market cap
- $20.9M
- Shares outstanding
- 11.57MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from TherapeuticsMD, Inc.
All →TherapeuticsMD Financial Results
TherapeuticsMD reported third quarter 2026 financial results, highlighting license revenue of $1.3 million, a 60.6% increase year-over-year. The company achieved a $0.5 million net income from continuing operations and ended the period with $10.4 million in cash. Management noted the achievement of a sales-based milestone for IMVEXXY and continues to evaluate strategic alternatives including potential mergers or asset sales.
- Term
- Q3 2026